CRISPR-dCas9 gene editing secreted alpha Klotho gene therapy (Klogene Therapeutics)

N/A

Report date: 2025/01/26 16:58:02

Base Information

Drug NameCRISPR-dCas9 gene editing secreted alpha Klotho gene therapy (Klogene Therapeutics)
Drug Alias NameAAV-based central nervous system gene therapy (Kogenix Therapeutics)secreted alpha Klotho gene therapy (Kogenix Therapeutics)
ClassificationBiologics
Mechanisms of ActionKlotho stimulants
TargetsKlotho
Therapy Area/IndicationsAlzheimer DiseaseDementia
Global Approved IndicationsN/A
Approved Indications in ChinaN/A
Original Approved Country/TerritoryN/A
Original Approved DateN/A
Country/TerritoryUnited States
CombinationsNo
Global Highest StatusPreclinical
Highest Status in ChinaN/A
Originator CompaniesUniversitat Autonoma De Barcelona
China Registration ClassN/A

Develop Information

Active CompaniesKlogene Therapeutics Inc
Inactive CompaniesKogenix Therapeutics Inc
Active IndicationsAlzheimer DiseaseDementia
Inactive IndicationsN/A

Other Information

ATC CodeN/A
Related LinksN/A